Loss of UHRF2 Is Associated With Non-small Cell Lung Carcinoma Progression

被引:16
|
作者
Jin, Chun [1 ]
Xiong, Dian [2 ]
Li, Hao-Ran [1 ]
Jiang, Jia-Hao [1 ]
Qi, Jian-Chao [3 ]
Ding, Jian-Yong [1 ]
机构
[1] Fudan Univ, Affiliated Zhongshan Hosp, Dept Thorac Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China
[2] Nanchang Univ, Affiliated Hosp 2, Dept Cardiothorac Surg, Nanchang 330000, Jiangxi, Peoples R China
[3] Fujian Prov Hosp, Dept Emergency Surg, Fuzhou 350001, Fujian, Peoples R China
来源
JOURNAL OF CANCER | 2018年 / 9卷 / 17期
关键词
NSCLC; UHRF2; 5-hmC; demethylation; CYCLE NETWORK; TET ENZYMES; 5-HYDROXYMETHYLCYTOSINE; GENOME; TDG; HYPERMETHYLATION; 5-METHYLCYTOSINE; EXPRESSION; TARGET;
D O I
10.7150/jca.25876
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent evidence indicated ubiquitin like with PHD and ring finger domains 2 (UHRF2) was involved in various human diseases, especially in cancer, however, its roles in cancer are still in dispute. Here, we found UHRF2 expression was decreased in lung cancer tissues compared with adjacent normal tissues by referring to the Oncomine Database, which was further identified by immunoblotting and quantitative real-time polymerase chain reaction assays. Secondly, we found knockdown of UHRF2 in A549 and 95-D cell lines enhanced the capability of proliferation, invasion and migration, while forced UHRF2 expression inhibited NSCLC cells proliferation,invasion and migration. Mechanistically, dot-blot and western blot assays indicated that the level of UHRF2 was positively correlated with 5-hmC level by affecting ten-eleven translocation 2 (TET2) expression. Clinically, UHRF2 downregulation is significantly correlated with a malignant phenotype, including larger tumor size and poor differentiation. Moreover, UHRF2 downregulated correlates with shorter overall survival(OS). Conclusion: Our findings indicate that UHRF2 is a tumor suppressor in NSCLC by influence TET2 expression and serve as a potential therapeutic target in NSCLC.
引用
收藏
页码:2994 / 3005
页数:12
相关论文
共 50 条
  • [1] Proliferation index and cell loss in non-small cell lung carcinoma
    Mangili, F
    Cigala, C
    Gattuso, C
    EUROPEAN JOURNAL OF CELL BIOLOGY, 1997, 72 : 90 - 90
  • [2] Aaptamine attenuates the proliferation and progression of non-small cell lung carcinoma
    Gong, Kaikai
    Miao, Shuang
    Yang, Lijuan
    Wu, Yan
    Guo, Jiwei
    Chen, Weiwei
    Dai, Juanjuan
    Du, Jing
    Xi, Sichuan
    PHARMACEUTICAL BIOLOGY, 2020, 58 (01) : 1044 - 1054
  • [3] Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma
    Fontanini, G
    Vignati, S
    Boldrini, L
    Chine, S
    Silvestri, V
    Lucchi, M
    Mussi, A
    Angeletti, CA
    Bevilacqua, G
    CLINICAL CANCER RESEARCH, 1997, 3 (06) : 861 - 865
  • [5] Cell loss and proliferation in non-small cell lung carcinoma: correlation with histological subtype
    Mangili, E
    Cigala, C
    Arrigoni, G
    Rovere, E
    Gattuso, C
    Santambrogio, G
    Garancini, P
    EUROPEAN JOURNAL OF HISTOCHEMISTRY, 1998, 42 (04): : 287 - 295
  • [6] Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma
    Mendes-da-Silva, P
    Moreira, A
    Duro-da-Costa, J
    Matias, D
    Monteiro, C
    JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 2000, 53 (04): : 184 - 187
  • [7] Chromosomal duplication accompanies allelic loss in non-small cell lung carcinoma
    Varella-Garcia, M
    Gemmill, RM
    Rabenhorst, SH
    Lotto, A
    Drabkin, HA
    Archer, PA
    Franklin, WA
    CANCER RESEARCH, 1998, 58 (20) : 4701 - 4707
  • [8] Expression profiles associated with disease progression in non-small cell lung cancer
    Frankenberger, C.
    Basu, S.
    Bild, N.
    Potti, A.
    Raponi, M.
    Wang, Y.
    Beer, D. G.
    Coon, J.
    Bonomi, P.
    Borgia, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Metastatic non-small cell lung cancer: Costs associated with disease progression
    Fox, Kathleen M.
    Brooks, John M.
    Kim, Jennifer
    AMERICAN JOURNAL OF MANAGED CARE, 2008, 14 (09): : 565 - 571